Add To Watchlist
Share URL
About The Company
Description
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally.
Read More
Overview
Value
0
Growth
23
Health
36
Management
59
Analyst Opinion
71
Total
47
All Scores Out Of 100
Best Features
- Liked by analysts
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Earnings have declined recently
- Income is not covering expenditure and investment
- Earnings are negative
- Has a high level of debt 0
- Poor earnings and cashflow growth 0
Latest News
Looking for Undervalued Penny Stocks? Use These Tips
PennyStocks | 12:35 Mon 22 May 2023
Read More →
Penny Stock Investing, 3 High-Growth Industries to Watch
PennyStocks | 12:00 Sun 21 May 2023
Read More →
Bioventus Inc. (BVS) Q1 2023 Earnings Call Transcript
Seeking Alpha | 04:53 Wed 17 May 2023
Read More →
Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023
GlobeNewsWire | 14:30 Wed 3 May 2023
Read More →
Market Peers
BVS
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
N/A
Revenue Growth (5 Year Average)
-1.58%
Ratings Consensus
Buy
Share Buybacks
N/A
Dividend Yeild (TTM)
N/A
Valuation
Value Score
0
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 3 USD ✔
Current Price: 2.9 USD
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-0.37%
PE/Earnings Growth
N/A
Price/Book
0.74x
Growth
Growth Score
23
- ✔ Revenue growth has improved this yeara
- ✔ 5 Year Average Earnings growth of 22.84% is higher than the market average (14.48%)
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Revenue growth of -1.58% is lower than the market average (10.97%)
- ✘ Earnings growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of -18.12% is lower than the market average (12.35%)
Revenue Growth
-1.58%
Earnings Growth
22.84%
Cashflow Growth
-18.12%
Health
Health Score
36
Altman Z Score
N/A
Piostroski Score
3.00
Debt/Equity
2.36x
Current Assets/Liabilities
1.35x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
1.65x
Management
Management Score
59
Average Buybacks/Dilution
N/A
Recent Buybacks/Dilution
0.58%
5 Year Price Volitility
54.10%
Return On Assets
-11.34%
Return On Capital Employed
9.17%
Return On Equity
-53.37%
Return On Free Cashflow
-5464.62%
Return On Investments
-3839.83%
Analysts
Analyst Opinion
71
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Bioventus Inc.
Currency
USD
Beta
0
Vol Avg
477014
Ceo
Dr. Henry C. Tung
Cik
0001665988
Cusip
09075A108
Exchange
NASDAQ Global Select
Full Time Employees
1160
Industry
Medical Devices
Sector
Healthcare
Ipo Date
2021-02-11
Address
4721 Emperor Boulevard
City
Durham
State
NC
Country
US
Zip
27703
Phone
800 396 4325
All financial data provided by FMP